Taisho Pharmaceutical Co., Ltd.

Hiroyuki Kakinuma

Takahiro Oi

Masakazu Sato

Hitomi Takahashi

Yohei Kobashi

Yuko Hashimoto

Hajime Asanuma

Hideaki Amada

Yuki Iwata

Fumiyasu Shiozawa

Kenichi Kawabe

Tomomichi Chonan

Yuko Tsuchiya

Takahiro Ol

A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided. Specifically, a 4-isopropyl-6-methoxyphenyl glucitol compound represented by the following formula (I), or a pharmaceutically acceptable salt thereof, is provided: 

4-isopropyl-6-methoxyphenyl glucitol compound

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein Rrepresents a hydrogen atom, etc., Rrepresents a methyl group, etc., Rrepresents a Calkyl group substituted with an amino group(s), etc., and Rrepresents a hydrogen atom, etc.

4-isopropylphenyl glucitol compounds as SGLT1 inhibitors

C-phenyl 1-thioglucitol compounds of the following formula (I) or pharmaceutically acceptable salts thereof or hydrates thereof: [wherein

C-phenyl 1-thioglucitol compound

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate. 

1-thio-D-glucitol derivatives

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by Formula (I) below or a pharmaceutically acceptable salt thereof or a hydrate thereof  

C-phenyl glycitol compound

There is provided a heteroaryl 5-thio-&#x3b2;-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient. 

Heteroaryl 5-thio-&#x3b2;-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same

There is provided a 5-thio-&#x3b2;-D-glucopyranoside compound of the following formula, which has an inhibitory effect on SGLT2 activity, or a pharmaceutically acceptable salt thereof or a hydrate thereof. There is also provided a pharmaceutical preparation, particularly a prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which comprises such a compound as an active ingredient. 

Aryl 5-thio-&#x3b2;-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same

An N-hydroxyformamidine compound of the following formula or a pharmaceutically acceptable salt thereof: wherein R, A and R are as defined herein. The compounds inhibit 20-HETE-producing enzymes, 20-HETE being involved in the effects of causing microvascular constriction or dilation in major organs (e.g., kidneys, cerebral blood vessels) or of inducing cell proliferation.

N-hydroxyformamidine derivatives

The present invention provides a method for preparing an aryl 5-thio-&#x3b2;-D-aldohexopyranoside derivative of Formula (III), which comprises reacting a 5-thio-D-aldohexopyranose derivative of Formula (I) with Ar-OH of Formula (II) in the presence of a phosphine represented by PRRRand an azo reagent represented by R&#x2014;N&#x2550;N&#x2014;Rin accordance with the following scheme 

Growing community of inventors

Tokyo, Japan

Hiroyuki Kakinuma